Oral Piritrexim for Metastatic Urothelial Cancer
Author Information
Author(s): R. de Wit, S.B. Kaye, J.T. Roberts, G. Stoter, J. Scott, J. Verweij
Primary Institution: Rotterdam Cancer Institute
Hypothesis
Is oral piritrexim an effective treatment for metastatic urothelial cancer?
Conclusion
Piritrexim appears to be an active agent in patients with metastatic urothelial cancer when administered as a 5-day, low-dose oral schedule.
Supporting Evidence
- Of 29 evaluable patients, one patient achieved a complete response of 19+ weeks duration.
- Ten patients achieved a partial response with a median duration of 22 weeks.
- The total response rate was 38%.
Takeaway
Doctors tested a new medicine called piritrexim on people with a type of cancer. It helped some of them feel better for a while.
Methodology
A phase II study with oral piritrexim in non-chemotherapy pretreated patients with metastatic urothelial cancer.
Limitations
Some patients were not evaluable for response due to toxicity or other reasons.
Participant Demographics
{"total_patients":33,"sex_ratio":"22 male / 11 female","age_median":65,"age_range":"41-76"}
Statistical Information
Confidence Interval
95% confidence interval 20-56
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website